Intravenous Valproate Sodium (Depacon) Aborts Migraine Rapidly: A Preliminary Report

Mathew, Ninan T.; Kailasam, Jayasree; Meadors, Lori; Chernyschev, Oleg; Gentry, Paula

doi:10.1046/j.1526-4610.2000.00125.x

Cited by 101 publications

(65 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consistent with this view, several agonists at GABA receptors have been used as prophylactic antimigraine drugs. In this context, valproate (Cutrer et al 1997a;Shaygannejad et al 2006), baclofen in a small open study (Hering-Hanit 1999), and gabapentin (Di Trapani et al 2000) may prevent migraine attacks, while valproate has also been suggested to be effective in the acute treatment of migraine in another small open trial (Mathew et al 2000). Despite the above clinical evidence, it should be kept in mind that not all of the aforementioned compounds are selective in their action at GABA receptors, and the mechanisms involved in their antimigraine effect remain unclear.…”

Section: Gaba Receptorsmentioning

confidence: 99%

Current and prospective pharmacological targets in relation to antimigraine action

Mehrotra

Gupta

Chan

et al. 2008

Naunyn-Schmied Arch Pharmacol

View full text Add to dashboard Cite

Migraine is a recurrent incapacitating neurovascular disorder characterized by unilateral and throbbing headaches associated with photophobia, phonophobia, nausea, and vomiting. Current specific drugs used in the acute treatment of migraine interact with vascular receptors, a fact that has raised concerns about their cardiovascular safety. In the past, α-adrenoceptor agonists (ergotamine, dihydroergotamine, isometheptene) were used. The last two decades have witnessed the advent of 5-HT 1B/1D receptor agonists (sumatriptan and second-generation triptans), which have a well-established efficacy in the acute treatment of migraine. Moreover, current prophylactic treatments of migraine include 5-HT 2 receptor antagonists, Ca 2+ channel blockers, and β-adrenoceptor antagonists. Despite the progress in migraine research and in view of its complex etiology, this disease still remains underdiagnosed, and available therapies are underused. In this review, we have discussed pharmacological targets in migraine, with special emphasis on compounds acting on 5-HT (5-HT 1-7 ), adrenergic (α 1 , α 2, and β), calcitonin gene-related peptide (CGRP 1 and CGRP 2 ), adenosine (A 1 , A 2 , and A 3 ), glutamate (NMDA, AMPA, kainate, and metabotropic), dopamine, endothelin, and female hormone (estrogen and progesterone) receptors. In addition, we have considered some other targets, including gamma-aminobutyric acid, angiotensin, bradykinin, histamine, and ionotropic receptors, in relation to antimigraine therapy. Finally, the cardiovascular safety of current and prospective antimigraine therapies is touched upon.

show abstract

Section: Gaba Receptorsmentioning

confidence: 99%

Current and prospective pharmacological targets in relation to antimigraine action

Mehrotra

Gupta

Chan

et al. 2008

Naunyn-Schmied Arch Pharmacol

View full text Add to dashboard Cite

show abstract

“…Mathews and colleagues reported on a cohort of 61 patients treating 66 attacks of acute migraine with rapid infusion of 300 mg of IV sodium valproate. 105 A reduction of moderate to severe pain to mild or no pain was achieved in 37 of 66 attacks at 30 minutes. An additional 11 attacks had a greater than 50% reduction of pain intensity.…”

Section: Intravenous Sodium Valproatementioning

confidence: 97%

Chronic Migraine

Cady

Durham

2015

Headache and Migraine Biology and Management

View full text Add to dashboard Cite

“…Furthermore, the effect of valproate is mimicked by the GABA-A agonist (muscimol) but not by the GABA-B agonist (baclofen), suggesting a GABA-A-mediated mechanism. Although valproate and divalproex are more often used in the preventive treatment of migraine, valproate also seems effective for acute treatment [ 33 ]. It is established that the substantia gelatinosa of the spinal cord receives descending 5-HT fi bers from the rostroventral medulla, and these fi bers connect with spinothalamic neurons [ 34 , 35 ].…”

Section: Valproate and Divalproexmentioning

confidence: 99%

Neuromodulators for the treatment of headache disorders and fibromyalgia

Krymchantowski¹,

Bryson²,

Lipton³

et al. 2008

Current Science Inc

View full text Add to dashboard Cite

Migraine and fibromyalgia are prevalent and disabling disorders with few preventive medications approved by the US Food and Drug Administration (FDA). Neuromodulators (or antiepileptic drugs; AEDs) are often effective in the treatment of these conditions. Divalproex sodium and topiramate are FDA-approved AEDs for migraine. For fibromyalgia, pregabalin has recently been approved in the United States. We review the use of AEDs in the preventive treatment of these highly prevalent disorders.

show abstract

Intravenous Valproate Sodium (Depacon) Aborts Migraine Rapidly: A Preliminary Report

Abstract: Intravenous valproate appears to be safe and effective for the acute treatment of migraine. Double-blind, placebo-controlled studies to further investigate the use of this agent in acute treatment of migraine attacks are warranted.

Cited by 101 publications

References 10 publications

Current and prospective pharmacological targets in relation to antimigraine action

Current and prospective pharmacological targets in relation to antimigraine action

Chronic Migraine

Neuromodulators for the treatment of headache disorders and fibromyalgia

Contact Info

Product

Resources

About